Vanguard Global Advisers
MGX icon

Vanguard Global Advisers’s Metagenomi Therapeutics MGX Stock Holding History

Vanguard Global Advisers’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.9K Hold
13,392
– – ﹤0.01% 3390
2026
Q1 		$17.9K Buy
+13,392
New +$20.8K ﹤0.01% 3344

Other funds holding MGX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Global Advisers's MGX Position: Q2 2026 in Review

Vanguard Global Advisers held its Metagenomi Therapeutics (MGX) position steady in Q2 2026 at 13,392 shares worth $15.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3390.

Vanguard Global Advisers first reported a position in MGX in Q1 2026 and has held it in 2 quarters since. The position peaked at $17.9K in Q1 2026. 40 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

  • Vanguard Global Advisers held 13,392 shares of Metagenomi Therapeutics worth $15.9K as of Q2 2026.
  • Vanguard Global Advisers left its Metagenomi Therapeutics share count unchanged in Q2 2026.
  • Metagenomi Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3390 holding.
  • Vanguard Global Advisers first reported a position in Metagenomi Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Metagenomi Therapeutics position peaked at $17.9K in Q1 2026.
  • 40 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.